HUP0102101A2 - Protein-tirozin-kináz inhibitor benzotiazolszármazékok és az ezeket tartalmazó gyógyszerkészítmények - Google Patents

Protein-tirozin-kináz inhibitor benzotiazolszármazékok és az ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0102101A2
HUP0102101A2 HU0102101A HUP0102101A HUP0102101A2 HU P0102101 A2 HUP0102101 A2 HU P0102101A2 HU 0102101 A HU0102101 A HU 0102101A HU P0102101 A HUP0102101 A HU P0102101A HU P0102101 A2 HUP0102101 A2 HU P0102101A2
Authority
HU
Hungary
Prior art keywords
group
protein tyrosine
pharmaceutical compositions
compositions containing
tyrosine kinase
Prior art date
Application number
HU0102101A
Other languages
English (en)
Inventor
Joel C. Barrish
Jagabandhu Das
John Wityak
Original Assignee
Bristol-Myers Squibb Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Co. filed Critical Bristol-Myers Squibb Co.
Publication of HUP0102101A2 publication Critical patent/HUP0102101A2/hu
Publication of HUP0102101A3 publication Critical patent/HUP0102101A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány tárgyát az általános képletű benzotiazolok - amelyképletben előnyösen p értéke 0-3; X1 és X2 hidrogénatom vagyegyüttesen oxo- vagy tioxocsoport; R1 hidrogén- vagy halogénatom,alkil- vagy alkoxicsoport; R2 és R4 hidrogénatom; R3 adott esetbenszubsztituált alifás, aliciklusos heterociklusos vagy (hetero)aromásszénhidrogéncsoport, vagy ilyennel szubsztituált karbonil-, karbamoil-vagy karboxicsoport; és R5 szubsztituált arilcsoport, ahol aszubsztituensek főleg halogénatomok) és/vagy alkilcsoport(ok) -éssóik, ezeket tartalmazó gyógyszerkészítmények, és protein-tirozin-kinázokkal összefüggésbe hozható betegségek, például immunológiairendellenességek kezelésére való alkalmazásuk képezik. Ó
HU0102101A 1997-11-10 1998-11-02 Protein tyrosine kinase inhibitor benzothiazole derivatives and pharmaceutical compositions containing them HUP0102101A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6504297P 1997-11-10 1997-11-10
PCT/US1998/023204 WO1999024035A1 (en) 1997-11-10 1998-11-02 Benzothiazole protein tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
HUP0102101A2 true HUP0102101A2 (hu) 2001-11-28
HUP0102101A3 HUP0102101A3 (en) 2002-11-28

Family

ID=22059964

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102101A HUP0102101A3 (en) 1997-11-10 1998-11-02 Protein tyrosine kinase inhibitor benzothiazole derivatives and pharmaceutical compositions containing them

Country Status (25)

Country Link
US (1) US6825355B2 (hu)
EP (1) EP1037632B1 (hu)
JP (1) JP2001522800A (hu)
KR (1) KR20010031912A (hu)
CN (1) CN1290165A (hu)
AR (1) AR017588A1 (hu)
AT (1) ATE315394T1 (hu)
AU (1) AU744281B2 (hu)
BR (1) BR9814956A (hu)
CA (1) CA2309319A1 (hu)
DE (1) DE69833224T2 (hu)
ES (1) ES2256969T3 (hu)
HU (1) HUP0102101A3 (hu)
ID (1) ID24289A (hu)
IL (1) IL135176A0 (hu)
NO (1) NO20002121L (hu)
NZ (1) NZ503491A (hu)
PE (1) PE129799A1 (hu)
PL (1) PL340727A1 (hu)
RU (1) RU2212407C2 (hu)
TR (1) TR200001312T2 (hu)
TW (1) TW510898B (hu)
UY (1) UY25242A1 (hu)
WO (1) WO1999024035A1 (hu)
ZA (1) ZA9810219B (hu)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130209A1 (en) * 1999-12-22 2003-07-10 Cheresh David A. Method of treatment of myocardial infarction
US20040214836A1 (en) * 1998-05-29 2004-10-28 Cheresh David A. Method of treatment of myocardial infarction
US20060258686A1 (en) * 1998-05-29 2006-11-16 Cheresh David A Method of treatment of myocardial infarction
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
MXPA01010292A (es) * 1999-04-15 2002-10-23 Squibb Bristol Myers Co Inhibidores ciclicos de la proteina tirosina cinasa.
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
ATE277044T1 (de) * 1999-10-06 2004-10-15 Boehringer Ingelheim Pharma Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
KR20020084116A (ko) * 2000-02-07 2002-11-04 애보트 게엠베하 운트 콤파니 카게 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도
GB0003254D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
KR100571161B1 (ko) * 2000-06-21 2006-04-17 에프. 호프만-라 로슈 아게 벤조티아졸 유도체
JP5000068B2 (ja) * 2000-08-11 2012-08-15 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド チロシンキナーゼのインヒビターとして有用な複素環化合物
EP1341771A2 (en) * 2000-11-29 2003-09-10 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
ES2200617B1 (es) 2001-01-19 2005-05-01 Almirall Prodesfarma, S.A. Derivados de urea como antagonistas de integrinas alfa 4.
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
BR0214019A (pt) 2001-11-09 2004-10-13 Boehringer Ingelheim Phamaceut Benzimidazóis úteis como inibidores de proteìna quinase
US6734179B2 (en) 2001-12-12 2004-05-11 Hoffmann-La Roche Inc. Benzothiazoles
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
RU2340605C2 (ru) 2002-06-27 2008-12-10 Ново Нордиск А/С Арилкарбонильные производные в качестве терапевтических средств
CA2744893A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
AU2003258061A1 (en) * 2002-08-02 2004-02-23 Salmedix, Inc. Therapeutic inhibitionof protein kinases in cancer cells
CA2494942A1 (en) * 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
AU2003255767A1 (en) * 2002-08-10 2004-02-25 Astex Technology Limited 3-(carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors
SE0202429D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
SE0202464D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Use of compounds
EP2426122A1 (en) * 2002-10-24 2012-03-07 Merck Patent GmbH Methylene urea derivative as RAF kinasse inhibitors
US7087761B2 (en) 2003-01-07 2006-08-08 Hoffmann-La Roche Inc. Cyclization process for substituted benzothiazole derivatives
EP1597256A1 (en) * 2003-02-21 2005-11-23 Pfizer Inc. N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
CA2516931C (en) * 2003-02-28 2014-09-09 Bayer Pharmaceuticals Corporation Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
EP1611128A2 (en) * 2003-03-28 2006-01-04 Pharmacia & Upjohn Company LLC Positive allosteric modulators of the nicotinic acetylcholine receptor
US20050008640A1 (en) * 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
PT1636585E (pt) 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
FR2864539B1 (fr) 2003-12-30 2012-10-26 Lvmh Rech Oligonucleotide et son utilisation pour moduler l'expression de la proteine-kinase c isoforme beta-1 comme agent de depigmentation cutanee
MXPA06007667A (es) 2004-01-06 2006-09-01 Novo Nordisk As Heteroaril-ureas y su uso como activadores de glucocinasa.
AU2005210474B2 (en) * 2004-01-30 2011-07-07 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding cassette transporters
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
EP1713780B1 (en) * 2004-02-05 2012-01-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
DE102004006808A1 (de) * 2004-02-11 2005-09-01 Grünenthal GmbH Substituierte 4,5,6,7-Tetrahydro-benzothiazol-2-ylamin-Verbindungen
US20050209284A1 (en) * 2004-02-12 2005-09-22 Boehringer Ingelheim Pharmaceuticals, Inc. Tec kinase inhibitors
FR2868421B1 (fr) * 2004-04-01 2008-08-01 Aventis Pharma Sa Nouveaux benzothiazoles et leur utilisation comme medicaments
US7550499B2 (en) * 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
PL1753760T3 (pl) 2004-05-24 2008-06-30 Hoffmann La Roche (4-metoksy-7-morffolin-4-ylobenzatiazol-2-ilo)amid kwasu 4-hydroksy-4-metylopiperydyno-1-karboksylowego
SE0401970D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Novel compounds
CA2586931C (en) 2004-11-05 2013-08-06 Paul Spurr Process for preparation of isonicotinic acid derivatives
SE0403117D0 (sv) * 2004-12-21 2004-12-21 Astrazeneca Ab New compounds 1
US7514460B2 (en) 2004-12-22 2009-04-07 4Sc Ag Benzazole analogues and uses thereof
MX2007008434A (es) * 2005-01-19 2007-07-25 Squibb Bristol Myers Co Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
EP2457901A1 (en) * 2005-03-14 2012-05-30 High Point Pharmaceuticals, LLC Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors
BRPI0609719B8 (pt) 2005-03-23 2021-05-25 Hoffmann La Roche derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2
DE602006017694D1 (de) * 2005-06-27 2010-12-02 Bristol Myers Squibb Co C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
WO2007002634A1 (en) * 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
AU2006261828A1 (en) * 2005-06-27 2007-01-04 Bristol-Myers Squibb Company N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP1896417B1 (en) 2005-06-27 2011-03-23 Bristol-Myers Squibb Company Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
ATE547396T1 (de) 2005-07-08 2012-03-15 Novo Nordisk As Dicycloalkylcarbamoyl-harnstoffe als glucokinase- aktivatoren
EP1904467B1 (en) 2005-07-14 2013-05-01 Novo Nordisk A/S Urea glucokinase activators
BRPI0616571A2 (pt) 2005-09-27 2011-06-21 Hoffmann La Roche oxadiazolil pirazol-piridiminas como antagonistas de mglur2, processo para sua preparação, composição farmacêutica que os contém e uso dos mesmo
US7960569B2 (en) * 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7910087B2 (en) * 2007-03-02 2011-03-22 University Of Massachusetts Luciferins
JP2008222084A (ja) * 2007-03-14 2008-09-25 Yamaha Motor Electronics Co Ltd 電動ゴルフカーのブレーキ劣化検出方法及びこれを用いた電動ゴルフカー
WO2008124393A1 (en) * 2007-04-04 2008-10-16 Irm Llc Benzothiazole derivatives and their use as protein kinase inhibitors
FR2928547B1 (fr) 2008-03-13 2012-03-09 Lvmh Rech Extrait de l'orchidee brassocattle marcella koss et son utilisation en tant qu'actif de depigmentation cutanee
EP2414346B1 (en) * 2009-04-02 2015-06-24 Merck Patent GmbH Autotaxin inhibitors
JP2012525389A (ja) 2009-04-27 2012-10-22 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 置換イソキノリン誘導体、医薬組成物、及びβ−セクレターゼ阻害剤としての使用方法
CN101701018B (zh) * 2009-11-05 2012-06-13 东南大学 2-(4-氨基喹唑啉基)苯并[d]噻唑类衍生物及其用途
JP2013522364A (ja) * 2010-03-23 2013-06-13 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 置換イミダゾ［１，２−ｂ］ピリダジン誘導体、医薬組成物、及びβ−セクレターゼ阻害剤としての使用の方法
EP2640708A1 (en) 2010-11-19 2013-09-25 Ligand Pharmaceuticals Inc. Heterocycle amines and uses thereof
PT2766359T (pt) * 2011-10-14 2016-07-14 Ambit Biosciences Corp Compostos heterocíclicos e utilização dos mesmos como moduladores de recetores tirosina-cinase de tipo iii
EP2888007B1 (en) * 2012-08-22 2019-09-18 Merck Sharp & Dohme Corp. Benzimidazole tetrahydrofuran derivatives useful as amp-activated protein kinase activators
CN103058954A (zh) * 2013-01-07 2013-04-24 盛世泰科生物医药技术(苏州)有限公司 一种[6-(5-氨基-2-甲基-苯氨基甲酰-苯并噻唑]-氨基甲酸叔丁酯的制备方法
WO2014146995A1 (en) * 2013-03-20 2014-09-25 F. Hoffmann-La Roche Ag Urea derivatives and their use as fatty-acid binding protein (fabp) inhibitors
WO2014168262A1 (en) * 2013-04-11 2014-10-16 D.D.P. Corporation Kinase inhibitors containing cyclopropane skeleton
EP2990027A1 (en) 2014-09-01 2016-03-02 Institut Curie Skin whitening peptide agents
KR102575327B1 (ko) * 2014-10-31 2023-09-07 유비이 가부시키가이샤 치환 디히드로피롤로피라졸 화합물
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
MX2017016908A (es) 2015-06-22 2018-08-15 Actelion Pharmaceuticals Ltd Inhibidores de nadph oxidasa 4.
KR102089122B1 (ko) * 2016-08-25 2020-03-13 주식회사 엘지화학 디아민 화합물 및 이를 이용하여 제조된 플렉시블 소자용 기판
CN107021937B (zh) * 2017-03-27 2019-06-21 沈阳药科大学 苯并噻唑甲酰胺类化合物及其应用
CN110582500B (zh) * 2017-05-04 2022-04-05 上海长森药业有限公司 双并环类核衣壳抑制剂和其作为药物用于治疗乙型肝炎的用途
AU2018285833A1 (en) * 2017-06-14 2020-01-02 European Molecular Biology Laboratory Bicyclic heteroaromatic urea or carbamate compounds for use in therapy
PT3692023T (pt) * 2017-10-02 2023-08-23 1St Biotherapeutics Inc Compostos de benzotiazol e métodos que os utilizam para tratar distúrbios neurodegenerativos
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
CN115594671B (zh) * 2021-07-08 2024-03-15 沈阳药科大学 苯并噻唑类衍生物及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966706A (en) * 1971-01-27 1976-06-29 Ciba-Geigy Ag 2,6-Dihydroxy-3-cyano-4-methylpyridine containing azo dyes which contain a functional amino group
JPS50140442A (hu) * 1974-04-16 1975-11-11
JPS5632549A (en) * 1979-08-27 1981-04-02 Toyo Ink Mfg Co Ltd Pigment composition
JPS62194251A (ja) * 1986-02-20 1987-08-26 Konishiroku Photo Ind Co Ltd 保存安定性が改良されたハロゲン化銀写真感光材料
US4970318A (en) * 1988-05-24 1990-11-13 Pfizer Inc. Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
IL90337A0 (en) 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
JPH0667923B2 (ja) * 1989-05-11 1994-08-31 東洋紡績株式会社 新規なベンゾチアゾール誘導体
JP2869561B2 (ja) 1989-05-22 1999-03-10 大塚製薬株式会社 血小板粘着抑制剤
US5296486A (en) 1991-09-24 1994-03-22 Boehringer Ingelheim Pharmaceuticals, Inc. Leukotriene biosynthesis inhibitors
CA2118425C (en) * 1993-02-19 1997-08-12 Akiro Kajihara Benzothiazolesulfonamide derivative, method for preparing the same, and use thereof
US5496816A (en) 1994-03-14 1996-03-05 Merck & Co., Inc. Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
TW513418B (en) 1996-07-31 2002-12-11 Otsuka Pharma Co Ltd Thiazole derivatives, their production and use
PT944645E (pt) 1996-12-06 2005-06-30 Vertex Pharma Inibidores da enzima conversora de interleucina 1beta
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
AU1507199A (en) 1997-12-15 1999-07-05 Yamanouchi Pharmaceutical Co., Ltd. Novel pyrimidine-5-carboxamide derivatives

Also Published As

Publication number Publication date
PL340727A1 (en) 2001-02-26
ES2256969T3 (es) 2006-07-16
ZA9810219B (en) 2000-06-22
BR9814956A (pt) 2000-10-03
AU1371999A (en) 1999-05-31
HUP0102101A3 (en) 2002-11-28
EP1037632B1 (en) 2006-01-11
TW510898B (en) 2002-11-21
NO20002121D0 (no) 2000-04-26
US20020123484A1 (en) 2002-09-05
KR20010031912A (ko) 2001-04-16
IL135176A0 (en) 2001-05-20
ID24289A (id) 2000-07-13
WO1999024035A1 (en) 1999-05-20
UY25242A1 (es) 2001-08-27
RU2212407C2 (ru) 2003-09-20
US6825355B2 (en) 2004-11-30
DE69833224T2 (de) 2006-09-28
CN1290165A (zh) 2001-04-04
TR200001312T2 (tr) 2000-09-21
NO20002121L (no) 2000-05-09
DE69833224D1 (en) 2006-04-06
AR017588A1 (es) 2001-09-12
ATE315394T1 (de) 2006-02-15
JP2001522800A (ja) 2001-11-20
PE129799A1 (es) 2000-03-08
EP1037632A1 (en) 2000-09-27
EP1037632A4 (en) 2002-08-21
NZ503491A (en) 2002-08-28
CA2309319A1 (en) 1999-05-20
AU744281B2 (en) 2002-02-21

Similar Documents

Publication Publication Date Title
HUP0102101A2 (hu) Protein-tirozin-kináz inhibitor benzotiazolszármazékok és az ezeket tartalmazó gyógyszerkészítmények
DE60326646D1 (de) Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
HUP0203142A2 (hu) Benzodiazepinszármazékok, eljárás a vegyületek előállítására, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0301213A2 (hu) Ciklin dependens kinázok amino-tiazol inhibitorai, ezeket tartalmazó gyógyszerkészítmények, előállításuk és alkalmazásuk
HUP0402352A2 (hu) Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
DE60214198D1 (de) Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
MY119238A (en) 8-quinolinzanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
DK0497658T3 (da) Anvendelse af (omega-(4-(2-pyrimidinyl)-1-piperazinyl)-alkyl)-1H-azolderivater til fremstilling af lægemidler til behandling af sygdomme i de kognitive funktioner
HUP0004595A2 (hu) Aciklikus metalloproteáz inhibitorok
HUP0103366A2 (hu) Citokin inhibítorként használható amidszármazékok
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
MY156407A (en) 5-phenylthiazole derivatives and use as p13 kinase inhibitors
ES2188584T3 (es) Derivados heterociclicos de amina.
NO944643D0 (no) Protein-kinase-C-hemmere
TR200200778T2 (tr) Pirazol türevleri.
HUP0200021A2 (hu) 4-(Heterociklikus szulfonamido)-5-metoxi-6-(2-metoxi-fenoxi)-2-fenil- vagy -piridil-pirimidinek, mint endothelin receptor antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ES2195419T3 (es) Inhibidores bencenosulfonamida de pde-iv y su uso terapeutico.
WO2001032652A3 (en) N-substituted carbamoyloxyalkyl-azolium derivatives
YU4903A (sh) N-/5-///5-alkil-2-oksazolil/metil/tio/-2-tiazolil/ karboksamidni inhibitori ciklin zavisnih kinaza
DE59408213D1 (de) Pyrrolidin- und oxazolidin derivate , ihre herstellung und ihre verwendung als thrombocyten-aggregations-hemmer
IT1250749B (it) Composti eterociclici ad attivita' a ii antagonista
MX2009001255A (es) Agente mejorador de la actividad de la proteina qunasa c que contiene un derivado de alquileter o una sal del mismo.
HUP0303272A2 (hu) Metabolikus modulátorként alkalmazható melonil-CoA dekarboxiláz inhibitor azol-származékok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0002853A2 (hu) 6,7-Helyzetben aszimmetrikusan diszubsztituált kinoxalinkarbonsav-származékok, és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
AR002016A1 (es) Derivados de 3-fenilisoquinoleina-1-(2h)-ona, procedimiento para su preparacion y medicamento y composicion farmaceutica que los contienen.

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished